CTLA4 and melanoma: Similarly, Yuan et al. showed that in a subset of melanoma patients who express NY-ESO-1, those who had measurable NY-ESO-1-specific CD4+ and CD8+ T cell responses experienced more frequent clinical benefit to anti-CTLA-4 ICI and a significant survival benefit as compared to patients with an undetectable specific T cell response [55].